...
首页> 外文期刊>Human Molecular Genetics >Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II).
【24h】

Two endoplasmic reticulum-associated degradation (ERAD) systems for the novel variant of the mutant dysferlin: ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II).

机译:突变dysferlin的新变体的两个内质网相关降解(ERAD)系统:泛素/蛋白酶体ERAD(I)和自噬/溶酶体ERAD(II)。

获取原文
获取原文并翻译 | 示例
           

摘要

Dysferlin is a type-II transmembrane protein and the causative gene of limb girdle muscular dystrophy type 2B and Miyoshi myopathy (LGMD2B/MM), in which specific loss of dysferlin labeling has been frequently observed. Recently, a novel mutant (L1341P) dysferlin has been shown to aggregate in the muscle of the patient. Little is known about the relationship between degradation of dysferlin and pathogenesis of LGMD2B/MM. Here, we examined the degradation of normal and mutant (L1341P) dysferlin. Wild-type (wt) dysferlin mainly localized to the ER/Golgi, associated with retrotranslocon, Sec61alpha, and VCP(p97), and was degraded by endoplasmic reticulum (ER)-associated degradation system (ERAD) composed of ubiquitin/proteasome. In contrast, mutant dysferlin spontaneously aggregated in the ER and induced eukaryotic translation initiation factor 2alpha (eIF2alpha) phosphorylation and LC3 conversion, a key step for autophagosome formation, and finally, ER stress cell death. Unlike proteasome inhibitor, E64d/pepstatin A, inhibitors of lysosomal proteases did not stimulate the accumulation of the wt-dysferlin, but stimulated aggregation of mutant dysferlin in the ER. Furthermore, deficiency of Atg5 and dephosphorylation of eIF2alpha, key molecules for LC3 conversion, also stimulated the mutant dysferlin aggregation in the ER. Rapamycin, which induces eIF2alpha phosphorylation-mediated LC3 conversion, inhibited mutant dysferlin aggregation in the ER. Thus, mutant dysferlin aggregates in the ER-stimulated autophagosome formation to engulf them via activation of ER stress-eIF2alpha phosphorylation pathway. We propose two ERAD models for dysferlin degradation, ubiquitin/proteasome ERAD(I) and autophagy/lysosome ERAD(II). Mutant dysferlin aggregates on the ER are degraded by the autophagy/lysosome ERAD(II), as an alternative to ERAD(I), when retrotranslocon/ERAD(I) system is impaired by these mutant aggregates.
机译:dysferlin是一种II型跨膜蛋白,是2B型肢带肌营养不良症和Miyoshi肌病(LGMD2B / MM)的致病基因,其中经常观察到Dysferlin标记的特异性缺失。最近,一种新型突变体(L1341P)dysferlin已显示在患者肌肉中聚集。关于dysferlin降解与LGMD2B / MM发病机理之间的关系知之甚少。在这里,我们检查了正常和突变(L1341P)dysferlin的降解。野生型(wt)dysferlin主要位于ER /高尔基体,与反转录转座子,Sec61alpha和VCP(p97)相关,并被由泛素/蛋白酶体组成的内质网(ER)相关的降解系统(ERAD)降解。相反,突变的dysferlin在ER中自发聚集,并诱导真核翻译起始因子2alpha(eIF2alpha)磷酸化和LC3转化,这是自噬小体形成的关键步骤,最后是ER应激细胞死亡。与蛋白酶体抑制剂E64d / pepstatin A不同,溶酶体蛋白酶抑制剂不会刺激wt-dysferlin的积累,但会刺激ER中突变的dysferlin的聚集。此外,Atg5的缺乏和eIF2alpha(LC3转化的关键分子)的去磷酸化也刺激了ER中突变的dysferlin聚集。雷帕霉素诱导eIF2alpha磷酸化介导的LC3转化,抑制ER中的突变dysferlin聚集。因此,突变的dysferlin聚集在ER刺激的自噬小体形成中,以通过激活ER应激-eIF2alpha磷酸化途径将其吞噬。我们提出了两种针对dysferlin降解的ERAD模型,泛素/蛋白酶体ERAD(I)和自噬/溶酶体ERAD(II)。当逆转录转运子/ ERAD(I)系统受到这些突变体聚集物的损害时,ER上的突变性dysferlin聚集体会被自噬/溶酶体ERAD(II)降解,以替代ERAD(I)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号